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22-Oxacalcitriol ameliorates high-turnover bone and marked to PTH hypersecretion in uremia is the reduced synthesis
osteitis fibrosa in rats with slowly progressive nephritis. of calcitriol in the kidney. Accordingly, active vitamin
Background. 22-Oxacalcitriol (OCT) is a unique vitamin D D sterols have been routinely used for its treatment [3, 4].
analogue with less calcemic activity than calcitriol, and it effec-
In severe cases, it has also been suggested that reducedtively suppresses parathyroid hormone (PTH) secretion in ure-
density of calcitriol receptor plays a role [5, 6]. Thus, inmic rats. This study was performed to examine the long-term
effect of intravenously administered OCT on high-turnover such patients, the intermittent administration of supra-
bone disease in model rats of slowly progressive renal failure. physiological doses of calcitriol also has been introduced
Methods. Slowly progressive renal failure rats were made as an option of treatment; it is known as calcitriol pulse
by a single injection of glycopeptide isolated from rat renal
therapy [7, 8]. Despite its effectiveness, this therapycortical tissues. At 250 days, glycopeptide-induced nephritis
sometimes must be discontinued because of hypercalce-(GN) rats were divided into three groups with the same levels
mia. Therefore, the development of an analogue ofof serum creatinine and PTH, and they received either OCT
(0.03 or 0.15 mg/kg body wt) or vehicle given intravenously calcitriol with low calcemic activity has been highly de-
three times per week for 15 weeks. sired.
Results. Renal function of GN rats deteriorated very slowly 22-Oxacalcitriol (OCT) is a synthetic analogue ofbut progressively, as assessed by the increase of serum creati-
calcitriol with less calcemic activity [9, 10]. The utility ofnine concentration. At sacrifice, serum PTH levels, bone forma-
this compound has already been examined in normaltion markers, bone resorption markers, and fibrosis volume
were significantly elevated in vehicle-treated GN rats compared and uremic animals, and several groups have reported
with those of sham-operated rats, suggesting the development successful suppression of PTH secretion and synthesis
of high-turnover bone disease with osteitis fibrosa. In contrast, without hypercalcemia [11–15]. Thus, OCT is a promis-in the GN-OCT 0.15 mg/kg group, these high PTH levels and
ing agent for the treatment of severe secondary hyper-high-turnover bone and fibrosis were significantly decreased.
parathyroidism in uremia. However, in these reportsSuch amelioration of bone abnormalities by OCT was not
accompanied by either hypercalcemia or further deterioration OCT was administered via the peritoneal route and only
of renal function. for a short period. Furthermore, the effects of OCT have
Conclusions. These data indicate that OCT may be a useful been examined and discussed exclusively in terms of
and safe agent not only for the suppression of PTH, but also PTH suppression. Only the short-term effects of OCTfor the amelioration of osteitis fibrosa and high-turnover bone
on bone abnormalities have been examined in normalwithout causing hypercalcemia in chronic dialysis patients.
rats [16] or in vitamin D-deficient mice [17], except for
a recent report with uremic dogs in which OCT pre-
vented or reversed abnormal bone formation but did notChronic dialysis patients often develop high-turnover
significantly alter the level of bone turnover [18].bone disease caused by excess parathyroid hormone
Most model animals used for long-term uremia have(PTH) [1, 2]. One of the principal mechanisms leading
been made by subtotal nephrectomy [19, 20]. However,
even in this model, uremia progresses more rapidly than
in humans and reaches its terminal phase almost withinKey words: renal failure, vitamin D, OCT, progressive renal disease,
bone turnover. 100 days [20]. This may limit the application of animal
data of bone to chronic dialysis patients.Received for publication April 8, 1999
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failure made by glycopeptide injection, in which model marker, tetracycline hydrochloride (Sigma, St. Louis,
MO, USA), at a dose of 20 mg/kg body wt was givenhigh-turnover bone disease with marked fibrosis caused
intraperitoneally for two days, followed by a labeling-by high PTH developed gradually over a year [21].
free interval of eight days and a second two-day adminis-
tration of the marker. The third lumbar vertebra from
METHODS each rat was fixed with 20% neutral-buffered formalin
Preparation of glycopeptide-induced nephritis rats after trimming the adhering soft tissues and was refixed
in 70% ethanol. Bone samples were then embedded inMale Wistar-Imamichi (WI) rats, three or four weeks
methyl methacrylate (MMA) after Villaneva’s stainingof age, were used for the preparation of glycopeptide-
[22]. With a microtome (Model Supercut 2050; Reichert-induced nephritis (GN) rats. GN rats were prepared
Jung, Heidelberg, Germany), 5 mm-thick serial unde-using a single injection of nephritogenic glycopeptide
calcified sections were obtained.isolated from rat renal cortical tissues by the method of
Histomorphometry was performed under microscopyShibata et al [21]. Five milligrams of the glycopeptide
using an image analyzing computer (Cosmozone 1SA;dissolved in 0.1 ml of physiological saline were combined
Nikon, Tokyo, Japan). The following parameters werewith the same volume of Freund’s incomplete adjuvant
measured and calculated: mineralized surfaces (MS/and were injected into the hind footpad of rats. The
BS %), bone formation rate (BFR/BS mm3/mm2/year),control rats received the adjuvant only. These rats had
mineral apposition rate (MAR mm/day), eroded surfacefree access to water and commercial standard rat chow
(ES/BS %), bone resorption rate (Rs.R mm2/mm2/year),(CE-2; Ca 1.18%, P 1.03%; Japan Crea, Tokyo, Japan).
osteoclast number (N.Oc/BS /mm), and fibrosis volumeThe animals used in this study were treated according
(Fb.V/TV %) The histomorphometric parameters wereto the ethical guidelines of animal care, handling, and
named and defined according to the nomenclature pro-termination at Chugai Pharmaceutical Co. Ltd. (Tokyo,
posed by the report from the ASBMR committee [23].Japan). These guidelines meet the generally accepted
international criteria of human treatment, which spares Blood and urine chemistries
the animals needless pain and ensures that the experi-
Serum phosphorus, urea nitrogen, and creatinine con-ments conducted are of actual scientific benefit to hu-
centrations were determined by autoanalyzer (Hitachimankind.
7170; Hitachi, Tokyo, Japan). Serum N-PTH concentra-
tions were measured by rat PTH kit (Immutopics Inc.,Treatment of glycopeptide-induced nephritis rats
San Clemente, CA, USA). The measurement of bloodby OCT
ionized calcium (iCa) was performed by automatic Ca11/
At 250 days after the injection of the glycopeptide, pH analyzer (THE 634 Ca11/pH Analyzer; Ciba-Corn-
the GN rats were divided into three groups of the same ing, Tokyo, Japan).
degree of secondary hyperparathyroidism according to Twenty-four–hour urine samples were collected from
the serum N-PTH concentration. The treatment groups rats placed in a metabolic cage. One milliliter of urine
were as follows: group 1, control vehicle (N 5 7); group sample and 250 ml of 25% trichloroacetic acid solution
2, GN vehicle (N 5 7); group 3, GN-OCT 0.03 mg/kg were mixed, and centrifuged at 1200 g for five minutes
body wt (N 5 7); and group 4, GN-OCT 0.15 mg/kg body at 48C. The precipitate was dissolved in 1 m sodium
wt (N 5 6). OCT was synthesized at Chugai Pharmaceu- chloride, and urinary protein was determined using the
tical Co. by being dissolved in phosphate-buffered saline solution by Biulet method.
(pH 8.0) containing 0.2% ethanol and 0.01% Tween 20.
The OCT solution or vehicle (volume 100 ml/100 g body Statistical analysis
wt) was administered intravenously three times per week All data were expressed as the mean 6 sem. Statistical
for 15 weeks. analysis was performed with SAS system. The Mann–
At 24 hours after the final administration of OCT, rats Whitney U-test was used for the comparison between
were sacrificed under diethylether anesthesia, and blood control group and GN-vehicle group. Nonparametric
samples were obtained from the abdominal aorta. Dunnett’s test (Steel’s test) was used for the comparison
of GN-vehicle group with GN-OCT groups. A P value
Bone histology and histomorphometry less than 0.05 was considered significant.
The tibias were fixed in 20% neutral-buffered formalin
and embedded in paraffin after ethylenediaminetetra-
RESULTSacetic acid (EDTA) decalcification. Longitudinal sec-
Progression of uremia and hyperparathyroidism intions of proximal epiphysis were made and stained with
glycopeptide-induced nephritis ratshematoxylin and eosin (HE).
For bone histomorphometric analysis, double labeling To determine the starting point of OCT therapy, the
progression of uremia and hyperparathyroidism wereof the bone was done in all rats before sacrifice. A bone
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and then progressively increased (P , 0.01; Fig. 1A).
The serum creatinine concentration in GN rats gradually
elevated and was significantly higher than that of control
rats after 200 days (P , 0.05; Fig. 1B). The serum N-PTH
level also gradually increased in GN rats and was signifi-
cantly higher than control rats after 200 days (P , 0.05;
Fig. 1C).
These results indicated that renal functions of GN rats
deteriorated slowly but progressively and that these rats
developed significant secondary hyperparathyroidism
after 200 days. At 250 days, the increase of osteoclast
number and fibrosis was confirmed by histology, sug-
gesting the development of high-turnover bone disease,
which was compatible with our previous reports with
GN rats [26, 27]. Thus, OCT was administered to these
model rats beginning from 250 days after glycopeptide
injection. At this point, GN rats had significantly higher
PTH levels (55.3 6 18.4 pg/ml) than those of control
rats (9.4 6 0.9 pg/ml).
Glycopeptide-induced nephritis rats were divided into
three groups at 250 days after glycopeptide injection
with the same levels of serum N-PTH, and they received
either OCT (0.03 or 0.15 mg/kg body wt) or vehicle given
intravenously three times per week for 15 weeks.
Suppression of PTH secretion by OCT in
glycopeptide-induced nephritis rats
Serum N-PTH levels in GN-vehicle rats were signifi-
cantly higher than that of control rats at the end of the
treatment period (P , 0.05; Table 1). In contrast, a
significant and dose-dependent suppression of increased
N-PTH concentration was observed in OCT-treated GN
rats. Such suppression of PTH was not accompanied by
a significant increase of either iCa or phosphate concen-
tration. OCT treatment did not worsen the residual renal
function either (Table 1).
These results indicated that long-term intravenous
OCT therapy suppressed PTH hypersecretion without
hypercalcemia or deterioration of renal function.
Amelioration of high-turnover bone and osteitis
fibrosa by OCT
At sacrifice, bone formation parameters such as miner-
alized surface (MS/BS), bone formation rate (BFR/BS),
Fig. 1. Time course of the changes in urinary protein (A), serum creati- and mineral apposition rate (MAR) were apparently
nine (B), and serum N-parathyroid hormone (PTH) (C) levels in glyco- elevated in vehicle-treated GN rats (Table 2). In addi-
peptide-induced nephritis (GN) rats or age-matched control (control)
tion, bone resorption parameters such as eroded surfacerats until 300 days after glycopeptide injection. Symbols are: (h) control;
(j) GN rats. *P , 0.05; **P , 0.01 vs. control. (ES/BS), bone resorption rate (Rs.R), and osteoclast
number (N.OC/BS) in vehicle-treated GN rats were also
elevated compared with vehicle-treated control rats (Ta-
ble 2). Furthermore, fibrosis volume (Fb.V/TV) was sig-
initially examined until 300 days after glycopeptide injec- nificantly elevated to as high as 5% (Fig. 2), with a higher
tion [21, 24, 25]. As shown in Figure 1, urinary protein level of serum N-PTH compared with that of vehicle-
significantly increased in GN rats compared with that of treated control rats (P , 0.05). A large number of active
osteoblasts and osteoclasts were observed in the proxi-control rats at 100 days after the injection of glycopeptide
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Table 1. Biochemical parameters at the end of the 22-oxacalcitriol (OCT) treatment
GN
OCT lg/kg
Parameters Control Vehicle 0.03 0.15
Urea nitrogen mg/dl 20.461.2 57.5 66.8a 53.362.0 56.963.2
Creatinine mg/dl 0.7260.03 1.59 60.15a 1.4460.11 1.5460.13
Ionized calcium nmol/litter 1.2560.03 1.22 60.02 1.3260.02 1.3260.03
Phosphorus mg/dl 7.660.5 9.6 61.1 9.461.0 10.460.9
N-PTH pg/ml 51.8632.7 806.96173.1a 286.46113.2b 216.2658.4b
a P , 0.05 vs. Control group
b P , 0.05 vs. Vehicle group
Table 2. Bone histomorphometry in the lumber vertebra at the end of the 22-oxacalcitriol (OCT) treatment
GN
OCT lg/kg
Parameters Control Vehicle 0.03 0.15
Bone formation parameters
MS/BS % 16.660.6 27.663.2 18.062.8 13.462.1b
BFR/BS lm3/lm2/year 39.862.3 116.3614.0a 67.6613.9b 42.267.9b
MAR lm/day 0.6660.03 1.1460.8a 1.0060.05 0.8360.07b
Bone resorption parameters
ES/BS % 21.460.5 33.062.1a 28.262.2 23.561.5b
Rs.R lm2/lm2/year 0.6160.00 1.6760.29a 1.0660.34 0.7660.19
N.Oc/BS /mm 0.6560.12 1.3660.24 0.7060.08 0.6760.2b
Abbreviations are: MS/BS, mineralizing surface; BFR/BS, bone formation rate; MAR, mineral apposition rate; ES/BS, eroded surface; Rs.R, bone resorption rate;
N.Oc/BS /mm, osteoclast number.
a P , 0.05 vs. Control group
b P , 0.05 vs. Vehicle group
mal area of tibia, and fibrosis increased strikingly in peri- cess PTH still remains the main feature of renal osteo-
trabecular bone (Fig. 3A). An increase of osteoid was dystrophy in chronic dialysis patients [1, 2], despite an
also observed in GN-vehicle rats (3.27 6 0.76%; control, increase in the prevalence of idiopathic adynamic bone
0.42 6 0.11%), but OV/BV was still low enough to be [29]. Treatment of high-turnover bone disease has been
classified into “osteitis fibrosa” according to Coburn’s aimed at ameliorating several stimuli for PTH secretion
criteria [28]. There was no decrease in serum concentra- such as hypocalcemia, hyperphosphatemia, and decreased
tions of calcitriol (control, 23.6 6 3.5; GN-vehicle, 36.8 6 production of calcitriol. For this purpose, calcium car-
5.9 pg/ml). These results indicated that GN rats devel- bonate and active vitamin D sterols such as calcitriol and
oped high-turnover bone disease with marked osteitis 1a-hydroxyvitamin D3 [1a(OH)D3] have been routinely
fibrosa at 350 days after injection of glycopeptide. used [3, 4]. In addition, the resistance of parathyroid cells
These elevated bone formation parameters were sig- to calcitriol because of the decreased density of the calci-
nificantly suppressed in OCT 0.15 mg/kg-treated GN rats triol receptor also has been recognized as a cause of para-
(P , 0.05; Table 2). Bone resorption markers were also thyroid hyperfunction in chronic renal failure [5, 6, 30].
apparently suppressed in OCT 0.15 mg/kg-treated GN Thus, supraphysiological doses of calcitriol by intermit-
rats (Table 2). Furthermore, the markedly elevated tent intravenous [7, 8] or oral [31, 32] administration
Fb.V/TV decreased significantly and dose dependently (calcitriol pulse therapy) have become popular treat-
by OCT treatment (P , 0.05; Fig. 2). As shown in ments for severe hyperparathyroidism in chronic dialysis
Figure 3B, massive fibrosis in peritrabecular bone was also
patients. However, there are still some patients who aremarkedly reduced by OCT treatment. However, increased
resistant to pulse therapy and who usually have markedosteoid was not reversed by OCT treatment (GN-vehicle,
parathyroid hyperplasia [6, 33, 34]. Furthermore, calci-3.27 6 0.76%; GN-OCT, 4.89 6 0.70%, P 5 NS).
triol pulse therapy often causes hypercalcemia, whereby
this therapy should be discontinued. Thus, it is necessary
DISCUSSION to develop a new vitamin D analogue that is stronger
and more selective to parathyroid.In chronic dialysis patients, several types of bone dis-
eases are often observed. Osteitis fibrosa caused by ex- 22-Oxacalcitriol was initially discovered as a synthetic
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These problems have not yet been fully answered, except
for a recent study with uremic dogs prepared using par-
tial nephrectomy, in which OCT therapy prevented or
ameliorated abnormal bone formation such as woven
osteoid and fibrosis, but did not significantly alter the
level of bone turnover [18].
In addition, a remnant kidney model of rats made by
5/6 nephrectomy is one of the most common models
used to assess the pathophysiological aspects of chronic
renal failure and the histological bone changes in uremia
[19, 20]. However, even in this model, uremia usually
progresses much faster than in humans; thus, their bone
changes may not reflect those in chronic dialysis patients.
To evaluate the long-term changes of bone in uremia,
we adopted the use of the GN model established by
Shibata et al [21, 24, 25]. We have previously examined
the bone change and the effect of 1a(OH)D3 in these
model rats [26, 27].Fig. 2. Fibrosis volume in lumbar vertebra of glycopeptide-induced
As shown in this article, renal functions in these modelnephritis (GN) rats treated with vehicle or 22-oxacalcitriol (OCT) for
15 weeks. Abbreviation is Fb.V/TV, fibrosis volume. Osteitis fibrosa rats deteriorated very slowly but progressively. Via histo-
was defined as Fb.V/TV . 0.5%. #P , 0.05 vs. control vehicle; *P , morphometry, we confirmed the development of severe0.05 vs. GN vehicle.
high-turnover bone disease and marked osteitis fibrosa
by high PTH compatible with our previous reports with
this model [26, 27]. In our model, fibrosis volume reached
analogue of vitamin D that may mimic certain actions to as high as 5% or more. Because fibrosis volume in
of calcitriol on cell differentiation [9, 10]. This analogue the remnant kidney model has been reported as up to
was soon recognized as a less calcemic agent for the 0.9% [18, 20], our model rats can serve as one of the
treatment of hyperparathyroidism. In addition to the first most severe models of osteitis fibrosa in uremia available.
report by Brown et al in normal rats [11], the usefulness The long-term intravenous administration of OCT not
of this analogue in the management of hyperparathyroid- only suppressed PTH hypersecretion, but also amelio-
ism in chronic renal failure was confirmed by other rated bone abnormalities in uremia without hypercalce-
groups [12–15]. In addition, OCT has been shown to mia. In these model rats, OCT treatment reversed high-
prevent the decrease of vitamin D receptor in parathy- turnover bone, as well as massive fibrosis, in sharp contrast
roid glands in uremic rats [35]. to the recent report with uremic dogs [18]. Such effects
This less calcemic action of OCT has been partly ex- of OCT on bone turnover were mainly achieved through
plained by its rapid metabolic clearance caused by the the suppression of PTH, although direct actions of OCT
very low affinity with vitamin D-binding proteins and on bone cells may have played a role, as suggested by
by selective tissue distribution [36–39]. In addition, the several reports [44–47].
attenuated action of OCT on intestinal calcium absorp- Furthermore, these favorable effects were achieved
with less significant hypercalcemia than in the uremiction through calcium-binding proteins, especially on
CaBP-D9K in the intestine, may be responsible for the dog model [18]. Such differences between their report
and ours can be explained by the differences in modelless calcemic effect of OCT [40–42].
In spite of these supportive data, there are still some and in species. Our model showed much more severe
bone abnormalities despite slower progression of uremiapoints to be clarified for the clinical application of OCT.
The first point is that OCT was administered via a perito- than their model. Difference in the degree of hypercalce-
mia can be explained by higher binding of OCT to vitaminneal route in most previous reports with animals. By
contrast, in clinical trials OCT is exclusively administered D-binding protein in dogs than in rats and humans [36].
By contrast, the oral administration of 1a(OH)D3 orvia an intravenous route [43]. The second point is that
OCT was administered as long as two weeks in most calcitriol in GN rats led to marked hypercalcemia in spite
of the short treatment in our previous reports [26, 27].previous studies. Thus, the possibility of a longer admin-
istration of OCT should be examined. The third point These differences, in turn, further support the notion
that our model can serve as a better model for renalis that the effects of OCT have been discussed only in
terms of PTH suppression. The long-term effect of OCT osteodystrophy in chronic dialysis patients than conven-
tional partial nephrectomy models.on high-turnover bone disease also should be clarified.
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Fig. 3. Effects of treatment by OCT for 15
weeks on peritrabecular fibrosis in the tibial
metaphysis of GN rats. (A) GN-vehicle (N-PTH:
617 pg/ml). Note the marked increase of active
osteoblast (arrow) osteoclast (arrow head), and
fibrosis (asterisk). (B) GN-OCT 0.15 mg/kg
(N-PTH 44.3 pg/ml). Note the decreased ac-
tive osteoblast and osteoclast numbers and
fibrosis.
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